Healio: Pioglitazone benefits decrease after discontinuing therapy

The protective effect of pioglitazone on type 2 diabetes prevention observed in adults with impaired glucose tolerance diminishes in the months after discontinuing therapy, with participants randomly assigned the drug progressing to diabetes at a rate similar to those assigned placebo, according to an analysis of the ACT NOW study.

Read the full story at Healio

Share This Article!